Scientists Halt FEM-PrEP Study in Africa

By Julie Turkewitz
From Housing Works

April 18, 2011

Scientists Halt FEM-PrEP Study in Africa

On Monday scientists terminated a study in Africa designed to figure out whether a daily oral dose of the antiretroviral Truvada could prevent women from becoming infected with HIV.

According to FHI, the global health organization conducting the study, early results showed no evidence that the pill was effective.

The study's premature termination disappointed AIDS activists who had high hopes for its results -- but excited others who oppose the FDA's potential approval of Truvada for this purpose.

In cased you missed it, here's the report from the New York Times.

Researchers to Wind Down HIV Prevention Trial in Women After Interim Results Find Drug Not Offering Protection From HIV

The FEM-PrEP HIV Prevention Study and Its Implications for NIAID Research

This article was provided by Housing Works. It is a part of the publication Housing Works AIDS Issues Update. Visit Housing Works' website to find out more about their activities, publications and services.

PrEP Ineffective for Women? Study on Truvada for HIV Prevention Is Unexpectedly Cut Short

Results of FEM-PrEP Clinical Trial Examining Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among Heterosexual Women

Global Campaign for Microbicides Statement on the Discontinuation of the FEM-PrEP Trial

The FEM-PrEP HIV Prevention Study and Its Implications for NIAID Research

More News and Research on HIV Medications for HIV Prevention

No comments have been made.

Add Your Comment:

(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

PrEP Ineffective for Women? Study on Truvada for HIV Prevention Is Unexpectedly Cut Short

Results of FEM-PrEP Clinical Trial Examining Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among Heterosexual Women

Global Campaign for Microbicides Statement on the Discontinuation of the FEM-PrEP Trial

The FEM-PrEP HIV Prevention Study and Its Implications for NIAID Research

More News and Research on HIV Medications for HIV Prevention

Newly Diagnosed? Words of Encouragement from HIV-Positive Women

HIV Management Today: Mental Health & HIV, the Uncharted Territory

Curing HIV Removes the Scars of the Past

Meth Makes an Ominous Comeback Among Gay Men

Can HIV-Positive People Have Babies? 7 Myths About Pregnancy and HIV/AIDS

More >>

TheBody.com App for iPhones

My Health Tracker

Medication and Health Reminders

Assess Your Risk for HIV

U.S. ASO Finder

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.